ANTHEM vs SAKAR: Stock Comparison
ANTHEM BIOSCIENCES is the larger company by market capitalisation. ANTHEM BIOSCIENCES shows a higher ROE, a higher dividend yield and lower leverage, while SAKAR HEALTHCARE shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ANTHEM leads 7; SAKAR leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ANTHEM | SAKAR |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Pharmaceuticals |
Price
| Metric | ANTHEM | SAKAR |
|---|---|---|
| Live Price | ₹915.55 | ₹975.55 |
| Day Change | 0.22% | -3.97% |
| Volume | 5.03 L | 86,756 |
| 52-Week High | ₹977.55 | ₹1,229.85 |
| 52-Week Low | ₹579.15 | ₹352.5 |
| Distance from 52W High | -6.34% | -20.68% |
Valuation
| Metric | ANTHEM | SAKAR |
|---|---|---|
| Market Cap | ₹51,405 Cr | ₹2,169 Cr |
| P/E Ratio | 83.61x | 50.6x |
| P/B Ratio | 15.62x | 6.27x |
| EPS | ₹2.13 | ₹5.08 |
| Book Value | ₹54 | ₹128.3 |
| Dividend Yield | 0.22% | 0% |
Growth
| Metric | ANTHEM | SAKAR |
|---|---|---|
| Revenue Growth (TTM YoY) | 26.4% | 40.1% |
| EPS Growth (TTM YoY) | 127.2% | 87.2% |
| Qtr Sales Growth | 0% | 19.79% |
| Qtr Profit Growth | 0% | 9.94% |
Profitability & Leverage
| Metric | ANTHEM | SAKAR |
|---|---|---|
| ROE | 21.06% | 10.68% |
| ROCE | 22.79% | 10.13% |
| Net Margin | 26.05% | 12.11% |
| Operating Margin | 43.54% | 18.91% |
| Debt to Equity | 0.01x | 0.26x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | ANTHEM | SAKAR |
|---|---|---|
| Promoter Holding | 71.4%▼ 0.02 pp | 51.7%▼ 0.82 pp |
| FII Holding | 3.79%▲ 1.21 pp | 12.34%▲ 0.21 pp |
| DII Holding | 12.1%▼ 1.38 pp | 11.92%▲ 0.55 pp |
| Public Holding | 12.7%▲ 0.17 pp | 24.04%▲ 0.06 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ANTHEM BIOSCIENCES and SAKAR HEALTHCARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.